Lei Ma

Lei Ma

Auto-generated profile, based on publicly available information

Lei Ma

Guangdong Provincial Key Laboratory of Molecular Target and Clinical Pharmacology, the State Key Laboratory of Respiratory Disease, The Third Affiliated Hospital & School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou 511436, China

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 November 2026 in Science Advances
Verified
Journal Article
Open access
XLXiawen Liu
Xiawen Liu
XZXiufen Zheng
Xiufen Zheng
LMLei Ma
Lei Ma
ZYZiqing Yao
Ziqing Yao
XZXuehua Zheng
Xuehua Zheng
WYWei Yi
Wei Yi
Polycystic ovary syndrome (PCOS), a prevalent multifactorial endocrine disorder, is inadequately managed by current therapies that fail to concurrently target its core metabolic (insulin resistance) and reproductive (hyperandrogenism) pathologies. We report VSP-51-2, a dual-target lead compound initially engineered as a selective PPARγ modulator that unexpectedly exerts potent uncompetitive inhibition of the androgen-synthesizing enzyme AKR1C3 through a putative allosteric mechanism. In preclinical PCOS models, VSP-51-2 restored regular estrous cyclicity, improved ovarian follicular morphology, enhanced systemic insulin sensitivity, suppressed hyperandrogenism, and did not significantly perturb measured hypothalamic-pituitary-ovarian (HPO) axis hormonal parameters. Mechanistically, it blocks PPARγ phosphorylation at Ser 273 , thereby enhancing adiponectin secretion and GLUT4-mediated glucose uptake, and is predicted to bind a putative allosteric pocket of AKR1C3 to constrain androgen biosynthesis. These findings support VSP-51-2 as a preclinical proof-of-concept compound for a dual-target strategy that addresses metabolic dysfunction and androgen excess through a unified molecular scaffold.